Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research

  ()
Proteostasis Therapeutics' shares traded higher after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021. read more >

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's

Research Report
  ()
How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. read more >

Avid Bioservices' Shares Rise on Q2/20 Earnings and Confirmed Outlook

  ()
Shares of Avid Bioservices traded higher, reaching a new 52-week high, after the firm reported Q2/20 earnings and reaffirmed its revenue guidance for Full-Year 2020. read more >

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck

  ()
ArQule Inc. shares traded more than 100% higher after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20. read more >
News Update

Antibiotic Alternative for Livestock Feed Approved for Malaysia

News Update
  ()
Now, the company has the green light to sell this product in eight countries. read more >

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

  ()
Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. read more >

Aurinia Pharma Shares Open 100% Higher on Phase 3 Lupus Data

  ()
Shares of Aurinia Pharmaceuticals traded much higher after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20. read more >

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

  ()
Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. read more >

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research initiates coverage on this clinical-stage biotech whose drug candidate works to strengthen the innate immune system. read more >

Immuno-Oncology Firm Expands Agreement with AbbVie

Research Report
  ()
The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. read more >

Expert Investing Ideas

"DRRX earned a $10M milestone payment from Gilead."

–Ed Arce, H.C. Wainwright & Co.


"The market for DRRX's POSIMIR could be substantial."

–Brian Marckx, Zacks Small-Cap Research


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

  ()
Axsome Therapeutics shares traded higher after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. read more >

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug

  ()
Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. read more >

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed

Research Report
  ()
The highlights of this investment story are outlined in a Zacks Small-Cap Research report. read more >
News Update

Regenerative Medicine Firm Advances Multifaceted Pipeline

News Update
  ()
The company continues advancing its cell therapies and medical device. read more >